3-phenylcoumarins bearing aminoalkoxy moiety has been designed to treat Alzheimer’s disease by inhibiting acetylcholinesterase and butyrylcholinesterase [51]. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.